Source notes

Diagnosing celiac disease in a child does not always require an intestinal biopsy, but avoiding one depends on strict conditions. The authors recommend initial blood tests for total IgA, a measure of one type of immune protein, and tissue transglutaminase IgA, an antibody associated with celiac disease. A specialist may diagnose without biopsy when the latter reaches at least 10 times the laboratory's upper normal limit and a different antibody test, EMA-IgA, is positive in a second blood sample. The family must agree to this pathway. A mildly positive test alone does not meet these conditions, even when symptoms seem convincing.

The threshold is relative to the specific laboratory test, not a universal number that can be copied between reports. Children with low total IgA need a different testing approach, and the no-biopsy rule cannot simply be transferred to their IgG antibody results. Symptoms or particular genetic markers are not mandatory for the carefully defined no-biopsy pathway. That does not mean symptoms and medical history are irrelevant to the overall assessment.

How Does This Show Up in Real Life?

For a family receiving a positive result, the useful question is what happens next, not whether the child should immediately start a lifelong restriction. The authors recommend specialist referral and continued adequate gluten intake during the diagnostic process. Starting a gluten-free diet too early can make confirmation harder. Some children will meet the blood-test criteria and can avoid tissue sampling. Others still need samples from the small intestine, including when antibody levels are below the required threshold. Needing a biopsy is not a sign that earlier testing was pointless; it means the result needs a different form of confirmation. The second blood sample in the no-biopsy pathway is also an essential safeguard, not an optional repeat. Parents should understand that either confirmed diagnostic route carries the same implication: ongoing gluten avoidance, not a temporary food experiment.

The supporting studies differ in test methods, participant selection, and diagnostic procedures. Evidence is less secure for some groups, including children without symptoms, and the authors identify further questions around children with type 1 diabetes. The recommendations address diagnostic accuracy rather than proving treatment outcomes. They do not establish that a particular testing route leads to better long-term health or easier dietary adherence after diagnosis.

The value here is a carefully controlled way to reduce unnecessary procedures while preserving diagnostic confidence. It is not a shortcut for interpreting a home test or a food reaction. The appropriate route depends on the child's complete results and specialist assessment, with an informed family involved.